March 2020 represented the 10th anniversary of the US biosimilars framework, marking a decade since the then-US president Barack Obama signed into law the Biologics Price Competition and Innovation Act as part of the Affordable Care Act.
However, it is only recently that the US has started to see the market edge toward maturity, in the form...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?